Ionis Pharmaceuticals (NASDAQ:IONS) slips 6% premarket on light volume following licensee Biogen’s Q2 report that included a relatively modest 15% jump in Spinraza (nusinersen) sales, an increase that appears to disappoint investors considering the company’s statement that it has not yet encountered a competitive threat from Novartis’ gene therapy Zolgensma (onasemnogene abeparvovec-xioi).
Spinraza sales were up 42% in Q1 and up 30% in Q4 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.